Uncomplicated urinary tract infections (uUTIs) remain a common outpatient diagnosis and the empiric treatment landscape has undergone meaningful change in recent years.1 Rising prevalence of multidrug-resistant uropathogens, particularly fluoroquinolone- and TMP-SMX-resistant E. coli, has narrowed the pool of reliable oral options and reinforced the clinical importance of local antibiogram data when selecting therapy.1,2 Updated classification frameworks now more precisely delineate uncomplicated from complicated presentations, sharpening the clinical criteria that determine which patients fall within uUTI-specific treatment algorithms.1,3
Current guideline-supported first-line agents include nitrofurantoin, fosfomycin, TMP-SMX, and pivmecillinam, each with distinct resistance profiles, tolerability, and cost considerations, and limitations in specific patient populations.3 TMP-SMX is increasingly limited by regional resistance rates exceeding 20% in many US markets, and fosfomycin, while convenient as a single oral dose, may demonstrate lower clinical or microbiologic efficacy against certain non-E. coli uropathogens, including Staphylococcus saprophyticus.4 Selection among these agents is guided by local antibiogram data, renal function, allergy history, and patient-specific tolerability.2
Against this backdrop, two agents have recently received FDA approval, representing the first newly approved oral uUTI treatments in the United States in decades. Pivmecillinam, a pivaloyloxymethyl ester of mecillinam used extensively in Europe, received US approval in 2024. Gepotidacin, a first-in-class triazaacenaphthylene antibacterial, was approved in 2025.6 Gepotidacin acts through dual inhibition of bacterial type II topoisomerases, DNA gyrase and topoisomerase IV, simultaneously. This dual-target mechanism is mechanistically distinct from fluoroquinolones and is associated with a lower likelihood of resistance emerging from single target-site mutations, a pharmacologic feature that may support more durable activity as prescribing evolves, though real-world resistance trends will require ongoing surveillance to confirm.
Clinicians managing uUTI now have more options, each warranting integration within a stewardship-informed framework.
Take our uUTI quiz to see how your knowledge compares to your peers.
